iiinova — where your digital self keeps evolving

One of the most powerful panel discussions I have seen in a long time; deep anger and outrage that parents are watching their children dying from rare diseases when treatments exist that could save their lives. @justtreatment.org @3rdworldnetwork.bsky.social

191

Now @dbdurisch.bsky.social @publiceye.ch showing how *2 days* after the @who.int transparency resolution was adopted in 2019, industry in Switzerland started a process to increase secrecy of drug prices - price transparency has got worse since then, not better

171

He argues for the need for standardization in *how* R&D costs are reported so this can be demanded from industry as part of health technology assessment

120

At the @wemos.org @hai-org.bsky.social #WHA78 side event on transparency where the Spanish Minister of Health highlights Pharma industry hypocrisy in saying they don’t know what their R&D costs are when this is the backbone of their justification for high prices

194

MSF Access @msfaccess.org · 15/05/2025

He argues for the need for standardization in *how* R&D costs are reported so this can be demanded from industry as part of health technology assessment

000

Reposted by Roz Scourse

⚠️ South Africa: Lifesaving scientific research on prevention, testing, treatment and care for people living with #HIV and #tuberculosis is under serious threat due to funding suspensions and grant terminations U.S. government. msfaccess.org/us-funding-c...

US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk

TAG and MSF urge donors to act now to protect ongoing research and ensure continuity of care for people with HIV and TB

23426

Reposted by Roz Scourse

Melissa Barber @mbarber.bsky.social · 13/05/2025

Incredibly sad news that the only Mycetoma research center in the world was destroyed in Khartoum. Scientists lost 40+ years of samples, a significant setback in the fight against an already neglected disease. www.theguardian.com/global-devel...

theguardian.com

Gleaming labs turned to rubble: scientists mourn the loss of decades of medical progress in Sudan

Universities and laboratories in Khartoum are looted or in ruins, with vital research and medicines destroyed, including pioneering work on tropical diseases

114684

Reposted by Roz Scourse

Shailly Gupta @shaillygupta.bsky.social · 24/04/2025

Access to TB drug bedaquiline was delayed for over a decade due to its high price. It was the public disclosure of significant public and non-profit investments in its development that supported a global movement leading to a price reduction of this lifesaving drug. msfaccess.org/call-transpa...

Call for transparency: detailed cost analysis of MSF’s TB-PRACTECAL clinical trial in PLOS Global Public Health

MSF published the costs of its landmark TB-PRACTECAL clinical trial in the journal PLOS Global Public Health that cost a total of €33.9 million.

064

This work continues with plans to publish more of MSF's clinical trial costs - as well as publication of trial costs by others who are starting to use the toolkit we developed as part of this work: msfaccess.org/transparency...

Transparency CORE: Clinical Trial Cost Reporting Toolkit

A toolkit to facilitate the analysis and publication of clinical trial costs

000

Despite claims by industry that publishing R&D costs cannot be done, MSF is showing by doing that transparency in R&D spending can and must be done; it is critical to determine fair prices of medical products, equitable access, and public accountability.

100

MSF has led some groundbreaking clinical trials, including TB-PRACTECAL. Recognising the lack of transparency in R&D costs, MSF took the unprecedented step to commit to publishing the costs of the clinical trials that we are involved in; TB-PRACTECAL cost €33.9 million: msfaccess.org/call-transpa...

Call for transparency: detailed cost analysis of MSF’s TB-PRACTECAL clinical trial in PLOS Global Public Health

MSF published the costs of its landmark TB-PRACTECAL clinical trial in the journal PLOS Global Public Health that cost a total of €33.9 million.

100

For decades the access to medicines community has called for more transparency in R&D costs. This is because the pharmaceutical industry continues to justify the high prices of medical products on high costs of R&D. These claims have never been backed up with evidence: msfaccess.org/secrets-cost...

Secrets Cost Lives: Transparency and Access to Medical Products

Progress towards equity in access to medical products can only be built on the open sharing of information and knowledge, not on secrets

100

Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens

Today in PLOS Global Public Health, MSF has published the costs of its landmark TB-PRACTECAL clinical trial. This is the first time the detailed costs of an individual clinical trial have ever been shared, challenging the lack of transparency in drug R&D costs 🧵 journals.plos.org/globalpublic...

journals.plos.org

Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontiè...

11312

Roz Scourse @rozscourse.bsky.social · 25/03/2025

Awesome to see Gary @garyseconomics.bsky.social at the wealth tax rally “I’m not very keen on rally’s. I always leave wondering if we can win. But I’m here cos I think we can win this one” #TaxTheSuperRich

011

Reposted by Roz Scourse

Jake Atkinson @jakeatkinson.bsky.social · 25/03/2025

NEW POLLING: 77% support ⬆️ taxes on the very richest over cuts to public spending 78% support a 2% wealth tax on net wealth over £10m 67% - think the very richest people in the UK should pay more in tax Tax the rich, don't punish the poor. @oxfamgb.bsky.social www.oxfam.org.uk/media/press-...

oxfam.org.uk

Oxfam GB | Three quarters of British public would back government tax increases on very richest versus spending cuts

01310

Reposted by Roz Scourse

Adam R Houston @healthlawadamh.bsky.social · 25/03/2025

New from us @plosglobalpublichealth.org "Cholera vaccines for the rich, #cholera for the poor: While the global cholera vaccine stockpile runs dry, a booming market for high-income countries exemplifies the chasm between commercial interests and global health needs" journals.plos.org/globalpublic...

15225

Roz Scourse @rozscourse.bsky.social · 25/03/2025

At most events on TB or HIV like this one for World TB Day, most speakers talk about their memories of how horrific the 80s and 90s were for these diseases in particular. Now with the massive aid cuts, there is clear fear of going backwards to anything close to those days

000

Reposted by Roz Scourse

Shailly Gupta @shaillygupta.bsky.social · 24/03/2025

Very timely message for the UK government. No country can and should back track from any aid commitments right now! #FundingCutsCostLives

051

World TB Day 2025: Open letter to the UK Government

The UK must reverse the aid cuts. The world's most vulnerable should not again face more cuts to vital, life-saving services. Read the letter here: msf.org.uk/article/worl...

msf.org.uk

Cuts to global TB services will have rapid and devastating impacts

000

The UK has an opportunity to show its commitment to TB and global health when co-hosting the Global Fund Replenishment later this year. No host country has ever reduced its pledge from the previous replenishment; we urge the UK to not be the first to do so.

100

In wasn't long ago that the UK committed to global efforts to end TB by 2030 as part of the TB political declaration. These efforts are already falling massively short of what's needed; this gap will only get much much worse in the face of these cuts

100

In our projects like in Uzbekistan, we are already seeing people with forms of TB that are resistant to almost all medicines, including newer drugs like Bedaquiline.

100

These cuts will have a catastrophic impact on TB services, especially in fragile and conflict-affected settings where MSF works. MSF has been involved in providing TB care for over three decades, treating more than 22,000 people each year.

100